Revolution Medicines RVMD 深 沪
等待开盘 04-02 09:30:00 美东时间
98.64
+1.390
+1.43%
华盛通- 最 高99.96
- 今 开98.67
- 成交量 218.60万股
- 最 低 97.19
- 昨 收 97.25
- 总市值 195.48亿
- 52周最高 124.49
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 34.00
- 委 比 99.54%
- 总股本 1.98亿
- 历史最高 124.49
- 量 比 1.06
- 振 幅 2.85%
- 历史最低 14.08
- 每 手 1
- 风险率 26.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares; $3,542,000 drops from sales on March 25, 2026
Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares; $3,542,000 drops from sales on March 25, 2026 Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, reported transactions in the company’s common stock dated 03/25/2026.
03-27 08:04
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines will present advances in its RAS(ON) inhibitor pipeline at the AACR Annual Meeting 2026. Key highlights include Phase 1 data for zoldonrasib in KRAS G12D mutant NSCLC, Phase 1/2 data for daraxonrasib in metastatic pancreatic cancer, and preclinical research on novel RAS(ON) inhibitors targeting resistance. The presentations demonstrate the company's broad RAS(ON)-focused strategy across multiple cancers.
03-17 22:37
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
美股盘后 | Equinox Gold Corp.涨4.73%，EOG能源涨2.02%
Equinox Gold Corp.涨4.73%；EOG能源涨2.02%；Teck Resources Limited Class B涨2.01%
03-13 06:11
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Tango Therapeutics reported a cash position of $343 million as of December 31, 2025, supporting operations into 2028. The company expects to initiate a pivotal study for vopimetostat in 2L MTAP-deleted pancreatic cancer in 2026. Vopimetostat combinations with RAS(ON) inhibitors in pancreatic and lung cancer are showing promising safety and efficacy. Initial Phase 1/2 data are anticipated in 2026. The company also entered a clinical supply agreeme...
03-05 12:00
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $145
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $150 to $145.
02-26 21:12
Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Earnings Call Insights: Revolution Medicines (RVMD) Q4 2025 Management View CEO Mark Goldsmith emphasized "substantial progress and growing momentum for our pioneering RAS(ON) inhibitor pipeline and o...
02-26 10:18
